Seeking Alpha

Prosensa data raises questions for Sarepta

  • Last week, Baird noted that DEMAND-III results for drisapersen would "have important implications for Sarepta (SRPT) as complete failure or overwhelming success would be a hard blow to the bull thesis." It appears the Phase 3 results out today may have dealt such a blow.
  • SRPT is off 10% premarket on news Prosensa (RNA) and GlaxoSmithKline's (GSK) drisapersen did not meet its primary endpoint in DMD114044.
  • Questions going forward: How valid are exon skipping drugs? Will the size of GSK's trial (186 boys) raise more questions about SRPT's data given the smaller size?
  • Look for sell-side to defend RNA, but for now, the shares are simply pricing in an end game: -76% premarket.
From other sites
Comments (1)
  • richard zorn
    , contributor
    Comment (1) | Send Message
    I just bought srpt pre market. Looks like a bullish sign to me.
    20 Sep 2013, 09:18 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs